Effect of Reducing Nucleotide Exposure on Bone Health (ReNew)

HIV/AIDS Clinical Trial

— ReNew  

Official title:

Effect of Reducing Nucleotide Exposure on Bone Health (ReNew)

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03549689
• Other study ID #: 43453
• Status: Withdrawn
• Phase: Phase 2
• Start date: August 1, 2019
• Est. completion date: July 1, 2021

Study information

• Verified date: March 2021
• Source: Stanford University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label, randomized pilot study to assess the effect on bone mineral density (BMD) of a switch from a tenofovir alafenamide-containing antiretroviral regimen to dolutegravir/lamivudine vs. a continuation of the tenofovir alafenamide-containing regimen.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: July 1, 2021
• Est. primary completion date: July 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. HIV-1 infection, as documented by a positive 4th generation assay or by any licensed ELISA test kit confirmed by Western blot at any time prior to study entry.

2. Age =18 years

3. HIV-1 RNA BLQ (e.g., <20 copies/mL or other threshold based on the local viral load assay used) for at least 12 months prior to study entry excluding blips (i.e., a single measurement <200 copies/mL preceded and followed by measurements BLQ)

4. On a stable TAF-containing ART that also includes at least 2 other antiretrovirals, with no changes in the 12 months prior to entry (except for a switch to a co-formulated tablet from the component tablets or a switch from ritonavir to cobicistat)

5. Lumbar spine, femoral neck or total hip BMD T-score =-1.0 from a DXA scan within the past 48 weeks

6. If receiving testosterone or estrogen replacement therapy, on a stable dose for =3 months prior to enrollment without plan to change dose during the study period.

7. Acceptable blood laboratory values at screening visit:

• CD4+ T-cell count =200 cells/µL
• Phosphate =2mg/dL
• 25-hydroxyvitamin D level =10 ng/ml
• Calculated creatinine clearance (CrCl) =50 mL/min as estimated by the

Cockcroft-Gault equation*:

• For men = CrCl (mL/min) = (140 - age in years) x (body weight in kg) ÷ (serum creatinine in mg/dL x 72) For women, multiply the above result by 0.85

8. For women of reproductive potential, negative serum or urine pregnancy test prior to screening and a negative urine pregnancy test at the entry visit prior to randomization and agreeable to using a contraceptive of choice during the study period. "Women of reproductive potential" are defined as women who have not been post-menopausal for at least 24 consecutive months (i.e., who have had menses within the preceding 24 months) and have not undergone surgical sterilization (i.e., hysterectomy, bilateral oophorectomy, or tubal ligation; participant report sufficient)

Exclusion Criteria:

1. Current systemic glucocorticoid use

2. Lumbar spine, femoral neck or total hip BMD T-score <-3.0

3. Previous, current pharmacologic treatment, or plan for initiation of therapy for osteoporosis (i.e., bisphosphonates, teriparatide, denosumab, tamoxifen or raloxifene)

4. Previous fragility fracture (i.e., any fall from a standing height or less that resulted in a fracture)

5. History of genotypic resistance or phenotypic resistance to either DTG or 3TC. The interpretation of genotypic resistance is based on output from the Stanford HIV Resistance Database (available at https://hivdb.stanford.edu). Isolates with an interpretation of low-level resistance or higher are considered resistant.

6. History of virologic failure (i.e., confirmed HIV-1 RNA level =200 copies/mL after over 6 months of therapy) while on an integrase inhibitor (i.e., raltegravir, elvitegravir, bictegravir, or dolutegravir) or on lamivudine/emtricitabine prior to study enrollment. Any antiretroviral history (even before routine virologic monitoring became standard of care) that would suggest the presence of the M184V mutation should be considered exclusionary

7. ALT =5 X ULN, OR ALT =3xULN and bilirubin =1.5xULN (with >35% direct bilirubin)

8. Severe hepatic impairment (Child Pugh Class C)

9. Anticipated need for antiviral therapy for HCV

10. Hepatitis B surface antigen positive or Hepatitis B DNA positive

11. Weight >300 pounds, precluding safe DXA testing

12. Breastfeeding, pregnancy, or plans to become pregnant during the study

13. Known allergy/sensitivity to DTG or 3TC.

14. Receipt or planned receipt of prohibited concomitant medications (See section 5.4)

15. Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study procedures and treatment.

16. Any serious medical or psychiatric illness that, in the opinion of the site investigator, precludes safe participation or adherence to study procedures.

Related Conditions & MeSH terms

• Bone Diseases, Metabolic
• HIV-1-infection
• HIV/AIDS
• Osteopenia

Intervention

Drug:
• Dolutegravir (DTG) 50MG/lamivudine (3TC) 300MG FIXED DOSE COMBINATION (FDC)
Participants randomized to the Switch Arm will take DTG 50mg/3TC 300mg FDC once daily with or without food at approximately the same time each day.
• Current tenofovir alafenamide (TAF)-containing ART regimen
Continuation of current TAF-containing ART for 96 weeks.

Locations

Country	Name	City	State
United States	Emory	Atlanta	Georgia
United States	University of Colorado	Aurora	Colorado
United States	Johns Hopkins	Baltimore	Maryland
United States	University of Alabama Birmingham	Birmingham	Alabama
United States	Northwestern	Chicago	Illinois
United States	Dallas VA Medical Center	Dallas	Texas
United States	UT Houston	Houston	Texas
United States	Columbia	New York	New York
United States	Stanford University	Palo Alto	California
United States	Penn	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Philip Grant

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percent change in lumbar spine Bone Mineral Density (BMD) at 96 weeks	Compare the percentage change from entry to 96 weeks in lumbar spine BMD in those randomized to DTG/3TC vs. those continuing a TAF-based regimen	Baseline and 96 weeks
Secondary	Percentage change in lumbar spine BMD at 48 weeks	Compare the percentage change from entry to 48 weeks in lumbar spine BMD in those randomized to DTG/3TC vs. those continuing a TAF-based regimen	Baseline and 48 weeks
Secondary	Percentage change in total hip BMD at 48 weeks	Compare the percentage change from entry to 48 weeks in total hip BMD in those randomized to DTG/3TC vs. those continuing a TAF-based regimen	Baseline, 48 weeks
Secondary	Percentage change in total hip BMD at 96 weeks	Compare the percentage change from entry to 96 weeks in total hip BMD in those randomized to DTG/3TC vs. those continuing a TAF-based regimen	Baseline, 96 weeks
Secondary	Change in CTX (a bone resorption marker)	Compare the changes in CTX from entry to 12, 48, and 96 weeks	Baseline, 12 weeks, 48 weeks, and 96 weeks
Secondary	Change in P1NP (a bone deposition marker)	Compare the changes in P1NP from entry to 12, 48, and 96 weeks	Baseline, 12 weeks, 48 weeks, and 96 weeks
Secondary	Change in urine ß2-microglobulin (renal tubular marker)	Compare the changes in urine ß2-microglobulin from entry to 48 weeks and 96 weeks.	Baseline, 48 weeks, and 96 weeks
Secondary	Change in urine RBP (renal tubular marker)	Compare the changes in RBP from entry to 48 weeks and 96 weeks.	Baseline, 48 weeks, and 96 weeks
Secondary	Change in urine protein	Compare the changes in protein from entry to 48 weeks and 96 weeks.	Baseline, 48 weeks, and 96 weeks
Secondary	Change in urine albumin	Compare the changes in urine albumin from entry to 48 weeks and 96 weeks.	Baseline, 48 weeks, and 96 weeks
Secondary	Change in fractional excretion in phosphate	Compare the changes in fractional excretion of phosphate from entry to 48 weeks and 96 weeks.	Baseline, 48 weeks, and 96 weeks
Secondary	Percentage change in total lean mass	Compare the percentage change from entry to 48 weeks and 96 weeks in total lean mass (as measured by whole body DXA)	Baseline, 48 weeks, and 96 weeks
Secondary	Percentage change in trunk fat	Compare the percentage change from entry to 48 weeks and 96 weeks in trunk fat (as measured by whole body DXA)	Baseline, 48 weeks, and 96 weeks
Secondary	Percentage change in limb fat	Compare the percentage change from entry to 48 weeks and 96 weeks in limb fat (as measured by DXA)	Baseline, 48 weeks, and 96 weeks
Secondary	Maintenance of HIV RNA level	Compare the levels of HIV RNA <50 copies/mL and below the limit of quantification (BLQ) at 48 weeks and 96 weeks using the FDA snapshot algorithm	48 weeks and 96 weeks
Secondary	Grade 3 or 4 adverse events	Compare rates of grade 3 or 4 adverse events experienced by participants through 96 weeks	96 weeks
Secondary	Treatment discontinuation of study medication due to adverse effect	Compare treatment discontinuation of study medication due to adverse effect experienced by participants through 96 weeks	96 weeks
Secondary	Change in fasting lipids	Compare changes in fasting lipids (total cholesterol, LDL, HDL, and triglycerides) at entry, 48 weeks, and 96 weeks	Entry, 48 weeks, and 96 weeks